chrisvoncsefalvay/vaers-outcomes huggingface dataset:
I received the vaccine in the afternoon and did fine in the evening aside from a low grade fever. The next morning at 10:30 AM I experienced severe nausea and my BP was dropping. I was taking care of a patient at work at the time. I went ahead and got the nurses to take care of my patient. I laid down for a little until the nausea passed The entire time I was very fatigued. I slept for an hour in my car. Then went back to work. I went home at 1:30PM because I felt so bad. I slept when I got home and into the next day. I had nausea, vomiting and diarrhea. I called in sick on Thursday and Friday and stayed in bed the whole time. I also had a swollen lymph node in my right clavicle area. I was still sick in bed all weekend all through Tuesday. The entire time I also experienced shortness of breath. I still experience the shortness of breath.  The shortness of breath was so bad I couldn't go a few feet to grab something with out having to take a rest. The shortness of breath has gotten me to a point where wearing a mask is difficult for me which was never the case. After having surgery, My stats kept dropping which is unusual for me. I also experienced pain in my shoulders. It feels like I am carrying a heavyweight backpack on my shoulder. I also am now experiencing chest wall pain. If I move around, I feel pain. It got to a point where I had to take a pain pill from my surgery and that did not help. I am scheduled for a echo on Thursday.
Slight pain and weakness in left arm injection site 12 days post injection; Slight pain and weakness in left arm injection site 12 days post injection; This is a spontaneous report from a contactable consumer, the patient. A 58-year-old male patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration in the left arm on 24Mar2021 at 13:00 (at the age of 58-years-old) as a single dose for COVID-19 immunisation. Medical history and concomitant medications were not reported. The patient did not have any allergies to food, medications, or other products  Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On an unknown date in Apr2021, the patient experienced slight pain and weakness in left arm injection site 12 days post injection. The patient did not receive any treatment for the adverse events. The adverse events did not result in  doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The clinical outcome of the events slight pain and weakness in left arm injection site 12 days post injection was not recovered at the time of this report.   No follow-up attempts are needed; information about lot/batch number cannot be obtained.
SKIN ALLERGIES; This spontaneous report received from a patient via a representative concerned a patient of unspecified age and sex. The patient's height, and weight were not reported. No past medical history or concurrent conditions were reported. The patient received covid-19 vaccine ad26.cov2.s (suspension for injection, route of admin not reported, batch number: Unknown) dose was not reported, administered on APR-2021 for prophylactic vaccination. The batch number was not reported. Per procedure, no follow-up will be requested for this case. No concomitant medications were reported.  On an unspecified date, the subject experienced skin allergies. The action taken with covid-19 vaccine ad26.cov2.s was not applicable. The outcome of skin allergies was not reported. This report was non-serious.
symptoms: fever, chills, body aches, headache, fatigue, diarrhea, profuse sweating time course: fever/chills/body aches symptoms began 6 hours after vaccination, lasted for 6 hours, had 6 hours respite, fever/chills/body aches/headache symptoms began and lasted for 6 hours, had 6 hours respite, headache/fatigue symptoms began and lasted 6 hours, had 6 hours respite, headache/fatigue/diarrhea/profuse sweating symptoms began and lasted 6 hours, had 6 hours respite, diarrhea symptoms for 6 hours
Patient received second Pfizer vaccine in January of 2021 and started experiencing numbness and tingling in legs, falling, patient felt as if the second vaccine exacerbated her MS symptoms. The results or outcome of the adverse event is unknown. "None of the above" was selected since there was no "unknown" selection.
As with my first vaccine in August, it took several hours then I start getting chilly then, after about two hours of that, I get the uncontrollable shivers for, 6 hours after the first shot and four hours after the second. Last night was hell. You should know that I had covid last year from June until October when I had to return to work or starve and get evicted. I have never really recovered completely.  My breathing is only about 75%  of capacity so I get winded easily. JOINT PAIN. After each vaccine shot, and the shivering stops, It feels like every one of my joints is inflamed and hurts so bad I can imagine what arthritis feels like.  Today, the day after the second shot I walk around in agony feeling like I have been hit by a bus. Same after the first vaccine in August. It will take me days to recover comfortably.  The joint pain was one of the major symptoms I had during covid last year and comes and goes every few months. I have had to retire from work due to the symptoms.  So, all this BS you release about the second dose being mild or no effects is just that, BS. I will never get another jab even if the Omega variant comes around.
Vaccine vial had been removed from deep freezer and placed into cooler longer that recommended time frame by Pfizer; Vaccine administered prior to having knowledge. Pharmacy contact Pfizer and ID physician; determined would not be harmful however would not be able to guarantee effectiveness. ID MD recommends offering revaccination after 3-4 weeks, which as been offered and accepted
This spontaneous report received from a nurse refers to a patient of unknown gender and age. Medical history was not provided. On 27-JAN-2014 the patient was vaccinated with VARIVAX (Merck) lot # 1944AA expiration date 12-DEC-2013 dose 1 (expired dose of VARIVAX (Merck)). No adverse event was reported. Additional information has been requested.
Information has been received from a physician concerning a patient who on an unspecified date was vaccinated with a dose of GARDASIL (route and lot # unknown) and experienced sweating and fainted at the physician's office. At the time of this report the patient's outcome was unknown. Follow up information has been received concerning the 12 year old female patient with no illness at the time of vaccination and with no known drug allergies, who on 03-AUG-2009 was vaccinated with the first dose of GARDASIL intramuscularly into her right upper extremity (lot # 662518/0087Y) at the private doctor's office/hospital with private funds at 12:30. It was reported that on 03-AUG-2009 the patient received the vaccine in the exam room, then walked to their checkout desk where she stood for approximately 3-4 minutes and then she lost consciousness and felt backwards. The patient was taken back to room and was placed O2 via nasal cannula, she stayed there until she fully recovered on 03-AUG-2009. This is one of several reports from the same source. No further information is available.
Patient came in for dose 1 Pediatric Pfizer 0.20 mg lot number FL8094.  At 5:00 pm drug accountability.   Pediatric syringe count at 12 noon was correct.  Noticed an error in drug accountability   It is possible that the patient received Adult dose Pfizer0.30 mg lot number FK9729.
parasthesia in the left arm and then hand and then then the left leg and foot, the symptoms were strong for about 1.5 hours and then subsided and 7 hours after the vaccine the symptoms had completely resolved.
Patient came in 10 days after she was vaccinated for her first dose of mmr and varivax.  She developed big red rash around parts of her body and erythematosis. She also developed fever of 101.9
Looks like permanent bandaid on arm after 1st shot; Arm swollen after 1st dose; Arm pain after 1st dose; This spontaneous case was reported by a consumer and describes the occurrence of LIMB DISCOMFORT (Looks like permanent bandaid on arm after 1st shot), PERIPHERAL SWELLING (Arm swollen after 1st dose) and PAIN IN EXTREMITY (Arm pain after 1st dose) in a 48-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 013a21a) for COVID-19 vaccination.     No Medical History information was reported.    On 20-Mar-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient experienced LIMB DISCOMFORT (Looks like permanent bandaid on arm after 1st shot), PERIPHERAL SWELLING (Arm swollen after 1st dose) and PAIN IN EXTREMITY (Arm pain after 1st dose). At the time of the report, LIMB DISCOMFORT (Looks like permanent bandaid on arm after 1st shot), PERIPHERAL SWELLING (Arm swollen after 1st dose) and PAIN IN EXTREMITY (Arm pain after 1st dose) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.       Concomitant product use was not provided by the reporter. Treatment information included cream.
Site: Redness at Injection Site-Medium, Site: Swelling at Injection Site-Medium, Additional Details: hardening as the site of the injection plus swollen.
approx 10 days p/vax pt showed generalized rash all over body. also listlessness, joint pains, slight fever & mild headache. seen in UCC was told viral illness. no meds given.
Information has been received from a certified medical assistant concerning an unspecified amount of patients. On unknown date the patients were vaccinated subcutaneously with 0.5 ml doses of (Oka/Merck) VARIVAX, that underwent temperature excursions. No adverse effect was reported.  Additional information has been requested.
scratchy feeling on the outside of her throat, dizzy and light headed. She carries an EPI pen for allergic reactions.
1/30/13 acute facial weakness. Peripheral 7th nerve palsy with classic facial nerve distribution involving upper & lower face. Rx: Prednisone x 6 day ZANTAC till gone
12 hours after injection  severe chills. Body aches. 102.0 fever. Very lethargic. Symptoms lasted 24 hours.
Patient back into clinic at 1520 pm with coughing, hives, red face and crying. 1525 PM gave albuterol sub treatment 02 oxy 86% before treatment, during treat was 94-98%; on 15L O2 via face mask. 1528pm Epi 1:1000 gave .15cc injection sq left leg 1535 pm once Benadryl given 11/ a top; 1545 Prednisone given 15mg ml O2 was 96-98% on RA; Hives disappear some
Initial unsolicited report received from a non health care professional on 19 Oct 2016. This case involves a 58-year-old female patient who was vaccinated with a dose of FLUZONE QIV (batch number: UF678AE, expiration date, dose not reported) via intramuscular route in the left deltoid on 04 Oct 2016. Patient medical history was not reported. Patient had no known allergies and illness at time of vaccination was reported as none. Any other vaccinations within 4 weeks of vaccinations were reported as none. Concomitant medication was not reported. On 04 Oct 2016, same day post vaccination; the patient experienced pain in arm radiating down arm and tingling and numbness in left arm. Lab data and corrective treatment was not reported. The patient was not recovered from the events. Follow-up information received from a non-health care professional on 18 November 2016. The patient had not received the FLUZONE QIV, patient had received FLUZONE QIV (batch number, expiry date, route, dose, dose in series were not reported) in an unknown site on an unknown date. This is not our product so there is no information on this. List of documents held by sender: none.
The patient was in the store and was offered the Covid-19 immunization as the pharmacy did not want to waste a dose from a Long Term Care Facility clinic completed that day. The patient accepted the vaccine and the normal procedures for entering a immunization were completed and the patient was vaccinated. On 3-30-21 the daughter called the Pharmacy to say patient did not need the second dose of Moderna Covid-19 as he had already received two doses of the Pfizer Covid-19 vaccine a number of weeks earlier.
13AUG92 pt recvd 1st dose of Engerix-B & devel severe fatigue & nausea; sx lasted about 6 hrs & resolved w/o tx;
pt recvd vax; sz & fever to 102 several hrs p/vax;pt nl at f/u exam w/in 45 mins;
receiving 2nd dose after 23 days of the first dose (instead of 28 days); This spontaneous case was reported by a nurse and describes the occurrence of INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (receiving 2nd dose after 23 days of the first dose (instead of 28 days)) in a  patient of an unknown age and gender who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.   On an unknown date, the patient received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On an unknown date, the patient experienced INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (receiving 2nd dose after 23 days of the first dose (instead of 28 days)). At the time of the report, INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (receiving 2nd dose after 23 days of the first dose (instead of 28 days)) had resolved.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   No concomitant medication details was provided. No treatment medication details was provided.   Most recent FOLLOW-UP information incorporated above includes: On 04-Feb-2022: Non-significant follow up
Chills Fatigue Fever Headache injection site redness swelling Pain Joint pain Muscle pain Nausea
Information has been received from physician and a registered nurse concerning the registered nurse's 7-year-old daughter who in approximately 1999, at 12-months-old, was vaccinated with a 0.5 mL dose of varicella virus vaccine live (Oka/Merck) (Lot # 628244/1343H). The child was exposed to chickenpox in the summer of 2005. On 10-AUG-2005, the patient developed a full-blown case of chickenpox with over 100 lesions/vesicles. A fever was noted. Acyclovir was prescribed. Subsequently, the patient fully recovered. No further information is available. Unspecified medical attention was sought. There was no product quality complaint. Additional information has been requested.
Child briefly lost consciousness after dropping to the floor. Became alert spontaneously. B/P - 120/70 P. 80 Pale & clammy; alert & oriented.  No incontinence or seizure activity. Was fine the next day.
pt walked from exam room to the front lobby & fainted; pt recv small (1cmx1cm) above right eyebrow; pt unconscious for <= 60 seconds; 02 administered et pt became conscious
ABOUT 5 MINUTES POST VACCINE, PATIENT REPORTED FEELING "ZONED OUT",  DESCRIBES "LIGHT HEADED, HOT, NAUSEATED. SHE THEN HAD SYNCOPAL EVENT FOR 5-10 SECONDS WAS CAUGHT BY PA WHO WAS AT HER SIDE. IMMEDIATELY RESPONSIVE, ALERT AND ORIENTED AFTER. BROUGHT TO TRIAGE 1 BY WHEELCHAIR WITH PA AT HER SIDE AND ASSISTED TO GUERNEY. SYMPTOMS SLOWLY ABATED, PALLOR IMPROVED.  BP 104/50 THEN 101/49 P 68, SPO2 96% ROOM AIR, BLOOD GLUCOSE 99.  RELEASED VIA WHEELCHAIR AFTER SITTING AND STANDING AT 5:23. EMT AND NP PASSED HER AND TRANSPORTATION ATTENDANT AT 5:27 AND PATIENT WAS RETURNED TO TRIAGE ARE DUE TO NAUSEA. PHYSICIAN AGAIN EVALUATED AND ORDERED ZOFRAN. WHICH WAS ADMINISTERED AT 5:30.
Symptoms: Abdominal pain, fever, runny nose, malaise. Treatment: Tylenol and Ibuprofen.
Very dry patches of palm of right and left hands.  Scaly and peals different size patch 1cm to 0.5cm size measured 3mm
flu-like symptoms; could not move for 12-14 hours; This case was reported by a consumer via call center representative and described the occurrence of influenza-like symptoms in a adult female patient who received Herpes zoster (Shingrix) for prophylaxis.   On an unknown date, the patient received Shingrix at an unknown dose. On an unknown date, unknown after receiving Shingrix, the patient experienced influenza-like symptoms and mobility decreased. On an unknown date, the outcome of the influenza-like symptoms was recovered/resolved and the outcome of the mobility decreased was resolved with sequelae.   It was unknown if the reporter considered the influenza-like symptoms and mobility decreased to be related to Shingrix.  Additional details were provided as follows: The age at vaccination was not reported. Post vaccination the patient felt flu like symptoms such that he could not move for 12 to 14 hours. The symptoms were resolved.  The reporter did not have any further details. This is 1 of 3 cases reported by the same reporter for different patients. The outcome of influenza-like symptoms was reported as recovered/resolved however in source document, it was mentioned as recovered/resolved with sequel.
This case was reported by a pharmacist (also the subject) and described the occurrence of chest tightness in a female subject of unspecified age who was vaccinated with FLULAVAL (GlaxoSmithKline). On an unspecified date the subject received a dose of FLULAVAL (details unknown). At an unspecified time after vaccination with FLULAVAL, the subject experienced chest tightness. At the time of reporting the outcome of the event was unspecified.
This case was reported by a consumer via call center representative and described the occurrence of dizziness in a 22-year-old female patient who received BOOSTRIX (batch number JP44F, expiry date unknown). Concurrent medical conditions included food allergy (pre-existing; worsened after the BOOSTRIX). On 9th January 2014, the patient received BOOSTRIX (intramuscular). In January 2014, 7 days after receiving BOOSTRIX, the patient experienced dizziness, headache, migraine, fatigue, palpitation, disorientation, memory deficit, mental concentration difficult, muscle pain and allergy aggravated. On an unknown date, the outcome of the dizziness, headache, migraine, fatigue, palpitation, disorientation, memory deficit, mental concentration difficult, muscle pain and allergy aggravated were recovering/resolving. The reporter considered the dizziness, headache, migraine, fatigue, palpitation, disorientation, memory deficit, mental concentration difficult, muscle pain and allergy aggravated to be related to BOOSTRIX. Additional details were received as follows: In January 2014, about 1 to 1 and half weeks after receiving BOOSTRIX, patient began experiencing dizziness, lightheadedness, fatigue, and headaches. Headaches were originally in morning and afternoon, and later spread throughout the day. Headaches then worsened into migraines. This worsening occurred about 2-3 weeks after BOOSTRIX administration. At that time, muscle pain, worsening allergies, heart palpitations, disoriented feeling, poor memory, and difficulty concentrating presented. Allergies further described as sensitivities to certain foods, chemicals, and weather. The reporter's call was transferred from the Center.
Headache, 102.2 temp, body aches, vomiting, nausea
This spontaneous report was received from a licensed practitioner nurse referring to a patient of unknown age and gender. Patient's medical history, concurrent conditions and concomitant medications were not reported. On 01-SEP-2015, the patient was vaccinated with the first dose of GARDASIL lot # L010596 and expiry date in 06-APR-2017, and then on 15-MAR-2016, the patient received the second dose of GARDASIL lot # K010215 and expiry date in 05-MAR-2017, both doses were administered intramuscularly (strength, dose and frequency were not reported). No adverse effects were reported and no product quality complaint was involved. Additional information has been requested.
Anaphylaxis; Initial information received on 04-Feb-2021 regarding an unsolicited valid serious case from the other health care professional and issued from a literature article.  This case is linked to case 2021SA039986 (same article).  This case involves a female patient of unknown age (current age is 44 year) who experienced anaphylaxis (anaphylactic reaction), after she received INFLUENZA VACCINE.  Medical history, medical treatment, concomitant medication, vaccination and family history were not provided.   On an unknown date, the patient received a dose of suspect INFLUENZA VACCINE produced by unknown manufacturer (lot number and expiry date: not reported) via an unknown route at an unknown administration site for unknown indication.  On an unknown date, the patient developed a serious anaphylaxis (anaphylactic reaction), unknown latency following the administration of INFLUENZA VACCINE. This event was assessed as medically significant.   It was also reported that the Brighton Collaboration case definition uses combinations of symptoms to define levels of diagnostic certainty. Brighton Level 1 represents the highest level of diagnostic certainty that a reported case is indeed a case of anaphylaxis. All patients should be instructed to seek immediate medical care if they develop signs or symptoms of an allergic reaction after their observation period ends and they have left the vaccination location. Health care providers can play an important role in vaccine safety by being vigilant in recognizing and reporting adverse events after immunization to VAERS (Vaccine Adverse Event Reporting System).  Details of laboratory data not reported.    This patient received Pfizer-BioNTech COVID-19 vaccine in Dec-2020 and within 34 minutes experienced anaphylaxis with generalized urticaria, swollen lips which required visit emergency department and treatment with Epinephrine.  It was unknown if patient received any corrective treatment.  At the time of reporting, the outcome of event was reported as unknown.  There will be no information available on the batch number for this case.; Sender's Comments: This case involves 44-year-old female patient who had anaphylactic reaction after vaccination with INFLUENZA VACCINE (unknown manufacturer). The time to onset is unknown. Additional information regarding patient's medical history, condition at the time of vaccination, lab data excluding other predisposing etiologies would be needed for complete assessment of the case. Based upon the reported information, the role of the vaccine cannot be assessed.
I95.9 HYPOTENSION 10/17/2021 CASE / CARE MGMT
sore arm; This is a spontaneous report received from contactable reporter(s) (Consumer or other non HCP). The reporter is the parent.  A 24 year-old male patient received bnt162b2 (BNT162B2), administered in arm left, administration date May2021 (Batch/Lot number: unknown) at the age of 24 years as dose 1, single for covid-19 immunisation. The patient had no relevant medical history. There were no concomitant medications. The following information was reported: PAIN IN EXTREMITY (non-serious) with onset 2021, outcome "unknown", described as "sore arm".  Additional information: Vaccination Facility Type: Hospital. The patient had no reaction to first dose aside from sore arm. The patient was not taking any other products. Investigation assessment was done. The reporter was not having the vaccination card at the time of the report to provide the date, lot, NDC or expiration dates of both doses. The dose was administered around 1700 or 1800. As per the reporter, the patient had been healthy. There was no history of all previous immunization with the pfizer vaccine considered as suspect (or patient age at first and subsequent immunizations if dates of birth or immunizations are not available. There were no additional vaccines administered on same date of the pfizer suspect. There was no prior vaccinations within 4 weeks. Apart from Covid vaccine no other prior vaccinations done. There was no relevant family medical history and no relevant tests done.  Follow-up activities closed. Batch/lot number not available for [Vaccine, BNT162B2], No further information is expected.